Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Drew M Pardoll

Showing results (11-20 of 285) with videos related to

Pageof 29
Sort By:
Seminars in Cancer Biology|April 3, 2002
Tumor immunology--towards a paradigm of reciprocal researchCharles G Drake, Drew M Pardoll
Journal for Immunotherapy of Cancer|January 24, 2025
Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of careSuzanne L Topalian, Drew M Pardoll
Immunological Reviews|June 19, 2015
Ubiquitin-dependent regulation of Foxp3 and Treg functionJoseph Barbi, Drew M Pardoll, Fan Pan
Oncoimmunology|July 4, 2012
Hypoxia-inducible factor 1: A link between metabolism and T cell differentiation and a potential therapeutic targetFan Pan, Joseph Barbi, Drew M Pardoll
Advances in Immunology|May 30, 2006
Mechanisms of immune evasion by tumorsCharles G Drake, Elizabeth Jaffee, Drew M Pardoll
International Journal of Cancer|February 11, 2005
Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigensJosef Mautner, Elizabeth M Jaffee, Drew M Pardoll
Molecular Cancer Therapeutics|November 9, 2005
Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunologyDan A Laheru, Drew M Pardoll, Elizabeth M Jaffee
The New England Journal of Medicine|August 30, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Drew M Pardoll
Cancer Journal (Sudbury, Mass.)|August 10, 2010
Cellular vaccine approachesDung T Le, Drew M Pardoll, Elizabeth M Jaffee
Science (New York, N.Y.)|February 1, 2020
Neoadjuvant checkpoint blockade for cancer immunotherapySuzanne L Topalian, Janis M Taube, Drew M Pardoll
Pageof 29

Showing results (11-20 of 285) with videos related to

Sort By:
Pageof 29
Seminars in Cancer Biology|April 3, 2002
Tumor immunology--towards a paradigm of reciprocal researchCharles G Drake, Drew M Pardoll
Journal for Immunotherapy of Cancer|January 24, 2025
Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of careSuzanne L Topalian, Drew M Pardoll
Immunological Reviews|June 19, 2015
Ubiquitin-dependent regulation of Foxp3 and Treg functionJoseph Barbi, Drew M Pardoll, Fan Pan
Oncoimmunology|July 4, 2012
Hypoxia-inducible factor 1: A link between metabolism and T cell differentiation and a potential therapeutic targetFan Pan, Joseph Barbi, Drew M Pardoll
Advances in Immunology|May 30, 2006
Mechanisms of immune evasion by tumorsCharles G Drake, Elizabeth Jaffee, Drew M Pardoll
International Journal of Cancer|February 11, 2005
Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigensJosef Mautner, Elizabeth M Jaffee, Drew M Pardoll
Molecular Cancer Therapeutics|November 9, 2005
Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunologyDan A Laheru, Drew M Pardoll, Elizabeth M Jaffee
The New England Journal of Medicine|August 30, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Drew M Pardoll
Cancer Journal (Sudbury, Mass.)|August 10, 2010
Cellular vaccine approachesDung T Le, Drew M Pardoll, Elizabeth M Jaffee
Science (New York, N.Y.)|February 1, 2020
Neoadjuvant checkpoint blockade for cancer immunotherapySuzanne L Topalian, Janis M Taube, Drew M Pardoll
Pageof 29